Tocris Bioscience™ Hydroxychloroquine sulfate

Description

Autophagy inhibitor; also TLR9 inhibitor

Autophagy inhibitor. Inhibits growth and induces apoptosis of renal cancer cells in vitro. Also inhibits TLR9. Additionally inhibits PRC2 by inhibiting the allosteric binding of PRC2 to EED (embryonic ectoderm development) within the H3K27me3-binding pocket, and reduces H3K27me3 levels in multiple myeloma cells in vitro.

Hydroxychloroquine sulfate is an autophagy inhibitor. Also inhibits TLR9. Inhibits growth and induces apoptosis of renal cancer cells in vitro. Additionally inhibits PRC2 by inhibiting the allosteric binding of PRC2 to EED (embryonic ectoderm development) within the H3K27me3-binding pocket, and reduces H3K27me3 levels in multiple myeloma cells in vitro. Inhibits SARS-CoV-2 viral infection, in vitro (EC50 values in μM range and dependent on viral RNA copy number). Hydroxychloroquine improves efficacy of adeno-associated viral gene transduction in vivo and in vitro. Also antimalarial and immunomodulator. Tocris products are for biomedical research use only. They are not intended for human or veterinary use.

Specifications

• Chemical Name or Material: 2-[[4-[(7-Chloro-4-quinolinyl)amino]pentyl]ethylamino]ethanol sulfate
• CAS: 747-36-4
• Quantity: 50 mg
• Target: Autophagy-related Compounds
• Molecular Formula: C₁₈H₂₈ClN₃O₅S
• Formula Weight: 433.95
• Purity: >99%